Notícias Fortress Biotech Inc - FBIO | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Fortress Biotech Inc (FBIO)
Fortress Biotech Inc (FBIO) Notícias

Fortress Biotech Inc (FBIO)

1,82

0,04

(2,25%)

Fechado 02 Fevereiro 6:00PM

Atrasado por 15 minutos

1,8299

0,0099

(0,54%)

Após o horário de negociação: 9:57PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Mustang Bio Announces Reverse Stock Split

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Fortress Biotech

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições